Blood pressure drug may ward off migraine
Posted on: Wednesday, 12 April 2006, 11:50 CDT
NEW YORK -- Treatment with the blood pressure drug olmesartan (sold as Benicar) effectively prevents migraine in patients with high blood pressure (hypertension) or pre-hypertension, a study hints.
Olmesartan belongs to a class of drugs called angiotensin II receptor blockers (ARBs).
In a previous study, the ARB candesartan was shown to be effective in the prevention of migraine in patients with hypertension or pre-hypertension. Therefore, Dr. James A. Charles, of New Jersey Medical School, Newark, and colleagues investigated whether this might also be true of olmesartan.
The study involved 24 hypertensive or pre-hypertensive patients with migraine who were treated with between 5 and 40 mg of olmesartan for between 3 months and 1 year.
After follow-up for at least 3 months, all but two patients reported a reduction in headache frequency and intensity. The frequency of migraine attacks was reduced by an average of 82.5 percent and there was an average reduction in migraine severity of 45 percent.
No serious side effects were reported, and none of the patients had to withdraw from the study because of medication intolerance. The only adverse events reported were light-headedness and dizziness.
The researchers note that efficacy was comparable to that seen in the candesartan trial.
They call for larger studies of ARBs in migraine prevention, noting that, in the current study, olmesartan "lacked the adverse effects of conventional migraine preventative drugs."
SOURCE: Headache March, 2006.
Source: REUTERS
Related Articles
- Obecure Recruits First Patient in Phase II Obesity Study in Pre-Menopause Women
- Researchers Tapped Thomson Reuters Community of Cancer Patients for Studies To Be Reported at American Society of Clinical Oncology Conference
- Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
- Cleviprex(TM) (Clevidipine Butyrate) Rapidly Reduced Blood Pressure and Maintained Control in Study of Patients With Acute Hypertension
- EPIX Pharmaceuticals Announces Positive Results From Phase 2a Clinical Trial of First-in-Class 5-HT2B Antagonist in Patients With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
- Danube Pharmaceuticals Initiates a Multi-Center Phase II Clinical Trial of DNB-001 in Patients With Ocular Hypertension
- The Medicines Company Supports Landmark Patient Observational Study and Clinical Survey on Acute Severe Hypertension
- SinoFresh Reports Patient Case Study: Allergic Fungal Rhinosinusitis in Adult Male With History of Sinus Conditions
- Genentech Stops Enrolling Patients in Study
- Bosentan Improves Exercise Tolerance and Tei Index in Patients With Pulmonary Hypertension and Prostanoid Therapy*
 |
 |
User Comments (0)
RSS Feeds